首页 > 市场调查报告书 > 製药

基因治疗学和RNAi

胜任细胞市场规模、份额及成长分析（按类型、应用、最终用户和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1899434

胜任细胞市场规模、份额及成长分析（按类型、应用、最终用户和地区划分）－2026-2033年产业预测

Competent Cells Market Size, Share, and Growth Analysis, By Type (Chemically Competent Cells, Electrocompetent Cells), By Application (Cloning, Subcloning & Routine Cloning), By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月17日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球胜任细胞市场规模将达到 23 亿美元，到 2025 年将达到 24.9 亿美元，到 2033 年将达到 46.4 亿美元，预测期（2026-2033 年）的复合年增长率为 8.1%。

受公共和私人领域对分子克隆研究投资不断增加的推动，全球胜任细胞市场正经历显着增长。大肠桿菌胜任细胞以能够整合染色体外DNA而闻名，可透过氯化钙处理和热休克等技术高效整合。这项特异性特性正推动着消费者对分子克隆产品的持续需求。此外，各项政府措施以及医疗保健支出的成长也对市场扩张产生了正面影响。人们对创新细胞技术的整体认知不断提高，加剧了生物技术领域的竞争格局。这些因素预计将推动全球胜任细胞市场取得重大发展，以满足全球科学研究和医疗保健产业不断变化的需求。

全球胜任细胞市场驱动因素

全球胜任细胞市场预计将持续成长，这主要得益于重组DNA技术产品开发需求的不断增长以及分子工程技术的进步。针对多种疾病的治疗药物研发活动的激增，预计将进一步推动市场扩张。有利的健保报销和法规环境也将对市场产生正面影响。此外，企业对分子克隆产品和重组蛋白日益增长的商业性兴趣，以及政府对倡议研究的投入不断增加，预计将显着推动市场发展，并在不久的将来为该行业带来强劲的成长势头。

全球胜任细胞市场限制因素

全球胜任细胞市场面临许多限制因素，可能阻碍其成长。其中一个主要障碍是胜任细胞试剂盒的高成本，这可能会限制部分使用者群体的取得。此外，市场整合程度的提高也提高了进入门槛，使得新进业者难以进入市场。同时，该领域经验丰富的专业人员匮乏也是一个挑战，这可能会阻碍胜任细胞在研究和应用中的创新和有效利用。这些因素共同构成了一个抑制市场扩张的环境。

全球胜任细胞市场趋势

受分子克隆产品需求成长和克隆研究进展的推动，全球胜任细胞市场预计将迎来显着成长。来自各机构的资金支持也进一步促进了市场扩张，而诸如体细胞核移植（SCNT）等创新细胞工程技术的出现，则开闢了包括基因改造动物开发和治疗性克隆在内的多元化应用领域。人们对保护濒危物种和加强生物製药研究的日益关注，并有望重新激发对胜任细胞在这些领域效用的兴趣，最终推动生物技术和医疗领域对胜任细胞的强劲需求。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Merck KGaA（Germany）
Promega Corporation（US）
Thermo Fisher Scientific, Inc.（US）
New England Biolabs（US）
Takara Bio（Japan）
Agilent Technologies（US）
Lucigen（Epicenter）（Illumina）（US）
QIAGEN NV（Germany）
OriGene Technologies（US）
Bioline（UK）
Zymo Research（US）
Beijing TransGen Biotech Co., Ltd.（China）
Source BioScience（UK）
IBA GmbH（Germany）
Genewiz（US）
BioDynamics Laboratory, Inc.（Japan）
GCC Biotech（India）
SMOBIO Technology（Taiwan）
GeneScript Corporation（US）
Bio-Rad Laboratories（US）

结论与建议

简介目录

Product Code: SQSG35H2024

Global Competent Cells Market size was valued at USD 2.3 Billion in 2024 and is poised to grow from USD 2.49 Billion in 2025 to USD 4.64 Billion by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).

The global competent cells market is experiencing significant growth, driven by increased investments from both public and private sectors in molecular cloning research. E. coli competent cells, known for their ability to take up extrachromosomal DNA, utilize methods like calcium chloride treatment and heat shock to enhance DNA integration. This unique characteristic promotes a steady demand for molecularly cloned products among consumers. Furthermore, various government initiatives, coupled with rising healthcare expenditures, contribute positively to market expansion. The overall awareness of innovative cellular techniques continues to grow, reinforcing the competitive landscape within the biotechnology sector. These factors collectively position the global competent cells market for substantial advancement, catering to the evolving needs of research and healthcare industries worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Competent Cells market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Competent Cells Market Segments Analysis

Global Competent Cells Market is segmented by Type, Application, End User and region. Based on Type, the market is segmented into Chemically Competent Cells and Electrocompetent Cells. Based on Application, the market is segmented into Cloning, Subcloning & Routine Cloning, Phage Display Library Construction, Toxic/Unstable DNA Cloning, High-throughput Cloning, Protein Expression, Other Applications, Mutagenesis, Single-stranded DNA Production, Lentiviral Vector Production and Large Plasmid Transformation. Based on End User, the market is segmented into Pharmaceutical and Biotechnology Companies, Academic Research Institutes and Contract Research Organizations (CROs). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Competent Cells Market

The Global Competent Cells market is poised for growth, fueled by the increasing demand for products developed through recombinant DNA technology and advancements in molecular engineering. A surge in research and development efforts focused on therapeutic products for various diseases is expected to further drive market expansion. Favorable reimbursement and regulatory environments will also contribute positively to this landscape. Furthermore, rising commercial interest in molecularly cloned products and recombinant proteins, coupled with heightened government investment in research initiatives, will significantly propel the market forward, reflecting a robust trajectory for the industry in the foreseeable future.

Restraints in the Global Competent Cells Market

The Global Competent Cells market faces several constraints that could hinder its growth. One significant obstacle is the high cost associated with competent cell kits, which can limit accessibility for various users. Additionally, the increasing consolidation within the market is raising entry barriers, making it challenging for new players to emerge. Furthermore, a shortage of experienced professionals in the field poses another challenge, as it may impede innovation and the effective use of competent cells in research and applications. Collectively, these factors contribute to a restrained environment for the expansion of the market.

Market Trends of the Global Competent Cells Market

The Global Competent Cells market is poised for significant growth, driven by the rising demand for molecularly cloned products and advancements in cloning research. Financial support from various organizations is further propelling market expansion, as innovative cell engineering techniques-like somatic cell nuclear transfer (SCNT)-unlock diverse applications, including the development of transgenic animals and therapeutic cloning. With the increasing focus on preserving endangered species and enhancing biopharmaceutical research, the utility of competent cells in these areas is set to see renewed interest, ultimately leading to a robust demand for competent cells in the biotechnological and medical sectors.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Analysis
Regulatory Analysis
Patent Analysis
Case Studies

Global Competent Cells Market Size by Type & CAGR (2026-2033)

Market Overview
Chemically Competent Cells
Electrocompetent Cells

Global Competent Cells Market Size by Application & CAGR (2026-2033)

Market Overview
Cloning
Subcloning & Routine Cloning
Phage Display Library Construction
Toxic/Unstable DNA Cloning
High-throughput Cloning
Protein Expression
Other Applications
Mutagenesis
Single-stranded DNA Production
Lentiviral Vector Production
Large Plasmid Transformation

Global Competent Cells Market Size by End User & CAGR (2026-2033)

Market Overview
Pharmaceutical and Biotechnology Companies
Academic Research Institutes
Contract Research Organizations (CROs)

Global Competent Cells Market Size & CAGR (2026-2033)

North America (Type, Application, End User)
- US
- Canada
Europe (Type, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Promega Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
New England Biolabs (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takara Bio (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lucigen (Epicenter) (Illumina) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OriGene Technologies (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioline (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymo Research (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beijing TransGen Biotech Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Source BioScience (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IBA GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genewiz (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioDynamics Laboratory, Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GCC Biotech (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SMOBIO Technology (Taiwan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GeneScript Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments